Symbols

CORT

Corcept Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 6

Bearish signal 0

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

High Cash/net Profit Ratio

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CORT

Corcept Therapeutics Incorporated

A commercial-stage pharmaceutical company that develops drugs to treat psychiatric/metabolic disorders assoiated with a steroid hormone cortisol

Industry

Pharmaceutical

Established Date

05/13/1998

Listing Date

04/14/2004

Exchange

NASDAQ Stock Exchange

Full-time Employees

730

Fiscal Year Ends

12-31

Website

www.corcept.com

Security Type

Common stock

Office address

101 Redwood Shores Parkway Redwood City CA 94065

Business

Introduction

Corcept Therapeutics Incorporated was incorporated in Delaware on May 13, 1998. The company is a commercial stage company engaged in the discovery and development of drugs to treat serious endocrine, tumor, metabolic and neurological diseases by regulating the action of the hormone cortisol.

Company Financials

EPS

CORT has released its 2025 Q4 earnings. EPS was reported at 0.2, versus the expected 0.25, missing expectations. The chart below visualizes how CORT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CORT has released its 2025 Q4 earnings report, with revenue of 202.13M, reflecting a YoY change of 11.12%, and net profit of 24.29M, showing a YoY change of -21.00%. The Sankey diagram below clearly presents CORT's revenue sources and cost distribution.